nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—hematologic cancer—muscle cancer	0.794	1	CtDrD
Ruxolitinib—RPS6KA6—embryo—muscle cancer	0.00141	0.0155	CbGeAlD
Ruxolitinib—PRKG2—smooth muscle tissue—muscle cancer	0.00124	0.0136	CbGeAlD
Ruxolitinib—PRKG2—renal system—muscle cancer	0.00119	0.0131	CbGeAlD
Ruxolitinib—PLK3—embryo—muscle cancer	0.00118	0.0129	CbGeAlD
Ruxolitinib—GRK7—head—muscle cancer	0.00105	0.0116	CbGeAlD
Ruxolitinib—ANKK1—head—muscle cancer	0.000961	0.0106	CbGeAlD
Ruxolitinib—ANKK1—testis—muscle cancer	0.000928	0.0102	CbGeAlD
Ruxolitinib—DCLK1—embryo—muscle cancer	0.000903	0.00993	CbGeAlD
Ruxolitinib—JAK1—embryo—muscle cancer	0.000903	0.00993	CbGeAlD
Ruxolitinib—PRKCE—tendon—muscle cancer	0.000867	0.00954	CbGeAlD
Ruxolitinib—RPS6KA6—tendon—muscle cancer	0.000833	0.00916	CbGeAlD
Ruxolitinib—PLK3—cardiac atrium—muscle cancer	0.000798	0.00877	CbGeAlD
Ruxolitinib—PRKG2—head—muscle cancer	0.000796	0.00876	CbGeAlD
Ruxolitinib—Myelosuppression—Dactinomycin—muscle cancer	0.000794	0.0704	CcSEcCtD
Ruxolitinib—ROCK1—embryo—muscle cancer	0.000778	0.00855	CbGeAlD
Ruxolitinib—PRKG2—testis—muscle cancer	0.000769	0.00846	CbGeAlD
Ruxolitinib—GRK1—head—muscle cancer	0.000759	0.00835	CbGeAlD
Ruxolitinib—PRKCE—head—muscle cancer	0.000743	0.00818	CbGeAlD
Ruxolitinib—DCLK3—vagina—muscle cancer	0.000733	0.00806	CbGeAlD
Ruxolitinib—PRKCE—testis—muscle cancer	0.000718	0.0079	CbGeAlD
Ruxolitinib—PLK1—head—muscle cancer	0.000714	0.00785	CbGeAlD
Ruxolitinib—RPS6KA6—head—muscle cancer	0.000714	0.00785	CbGeAlD
Ruxolitinib—MAST1—head—muscle cancer	0.000714	0.00785	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—muscle cancer	0.00071	0.00781	CbGeAlD
Ruxolitinib—Myelosuppression—Vincristine—muscle cancer	0.00071	0.0629	CcSEcCtD
Ruxolitinib—PLK1—testis—muscle cancer	0.00069	0.00759	CbGeAlD
Ruxolitinib—RPS6KA6—testis—muscle cancer	0.00069	0.00759	CbGeAlD
Ruxolitinib—MAST1—testis—muscle cancer	0.00069	0.00759	CbGeAlD
Ruxolitinib—JAK1—renal system—muscle cancer	0.000683	0.00752	CbGeAlD
Ruxolitinib—DCLK3—head—muscle cancer	0.000677	0.00745	CbGeAlD
Ruxolitinib—DCLK3—testis—muscle cancer	0.000654	0.00719	CbGeAlD
Ruxolitinib—CAMK1—tendon—muscle cancer	0.00065	0.00715	CbGeAlD
Ruxolitinib—PLK3—vagina—muscle cancer	0.000645	0.0071	CbGeAlD
Ruxolitinib—HIPK2—renal system—muscle cancer	0.000638	0.00702	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—muscle cancer	0.000637	0.007	CbGeAlD
Ruxolitinib—MARK2—tendon—muscle cancer	0.000631	0.00694	CbGeAlD
Ruxolitinib—DAPK3—renal system—muscle cancer	0.000613	0.00674	CbGeAlD
Ruxolitinib—JAK1—cardiac atrium—muscle cancer	0.000612	0.00673	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—muscle cancer	0.000611	0.00672	CbGeAlD
Ruxolitinib—CLK2—renal system—muscle cancer	0.000607	0.00668	CbGeAlD
Ruxolitinib—CAMK1—vagina—muscle cancer	0.000603	0.00664	CbGeAlD
Ruxolitinib—CAMK1D—cardiac atrium—muscle cancer	0.000597	0.00657	CbGeAlD
Ruxolitinib—PLK3—head—muscle cancer	0.000596	0.00656	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—muscle cancer	0.000594	0.00653	CbGeAlD
Ruxolitinib—ROCK1—renal system—muscle cancer	0.000589	0.00647	CbGeAlD
Ruxolitinib—TAOK2—tendon—muscle cancer	0.000584	0.00643	CbGeAlD
Ruxolitinib—DAPK2—cardiac atrium—muscle cancer	0.000584	0.00642	CbGeAlD
Ruxolitinib—PLK3—testis—muscle cancer	0.000576	0.00633	CbGeAlD
Ruxolitinib—LTK—head—muscle cancer	0.000576	0.00633	CbGeAlD
Ruxolitinib—Myelosuppression—Etoposide—muscle cancer	0.000575	0.051	CcSEcCtD
Ruxolitinib—RET—embryo—muscle cancer	0.000575	0.00632	CbGeAlD
Ruxolitinib—DYRK1A—renal system—muscle cancer	0.000574	0.00631	CbGeAlD
Ruxolitinib—BMPR2—renal system—muscle cancer	0.000572	0.00629	CbGeAlD
Ruxolitinib—CAMK1—head—muscle cancer	0.000557	0.00613	CbGeAlD
Ruxolitinib—LTK—testis—muscle cancer	0.000556	0.00612	CbGeAlD
Ruxolitinib—DAPK3—cardiac atrium—muscle cancer	0.000549	0.00604	CbGeAlD
Ruxolitinib—CLK2—cardiac atrium—muscle cancer	0.000544	0.00598	CbGeAlD
Ruxolitinib—JAK2—embryo—muscle cancer	0.000543	0.00597	CbGeAlD
Ruxolitinib—TAOK2—vagina—muscle cancer	0.000542	0.00596	CbGeAlD
Ruxolitinib—MARK2—head—muscle cancer	0.000541	0.00595	CbGeAlD
Ruxolitinib—CAMK1—testis—muscle cancer	0.000539	0.00592	CbGeAlD
Ruxolitinib—JAK1—tendon—muscle cancer	0.000533	0.00587	CbGeAlD
Ruxolitinib—DCLK1—tendon—muscle cancer	0.000533	0.00587	CbGeAlD
Ruxolitinib—MARK2—testis—muscle cancer	0.000523	0.00575	CbGeAlD
Ruxolitinib—CAMK1D—tendon—muscle cancer	0.000521	0.00573	CbGeAlD
Ruxolitinib—PHKG2—tendon—muscle cancer	0.000518	0.00569	CbGeAlD
Ruxolitinib—JAK1—bone marrow—muscle cancer	0.000517	0.00568	CbGeAlD
Ruxolitinib—PLK4—bone marrow—muscle cancer	0.000514	0.00565	CbGeAlD
Ruxolitinib—BMPR2—cardiac atrium—muscle cancer	0.000512	0.00563	CbGeAlD
Ruxolitinib—DAPK2—tendon—muscle cancer	0.000509	0.0056	CbGeAlD
Ruxolitinib—LRRK2—renal system—muscle cancer	0.000507	0.00558	CbGeAlD
Ruxolitinib—STK16—tendon—muscle cancer	0.000501	0.00551	CbGeAlD
Ruxolitinib—HIPK2—tendon—muscle cancer	0.000498	0.00548	CbGeAlD
Ruxolitinib—JAK1—vagina—muscle cancer	0.000495	0.00544	CbGeAlD
Ruxolitinib—DCLK1—vagina—muscle cancer	0.000495	0.00544	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—muscle cancer	0.000493	0.00542	CbGeAlD
Ruxolitinib—TAOK2—testis—muscle cancer	0.000484	0.00532	CbGeAlD
Ruxolitinib—CAMK1D—vagina—muscle cancer	0.000483	0.00531	CbGeAlD
Ruxolitinib—DAPK3—tendon—muscle cancer	0.000478	0.00526	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—muscle cancer	0.000478	0.00526	CbGeAlD
Ruxolitinib—PLK1—Teniposide—Etoposide—muscle cancer	0.000475	0.153	CbGdCrCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—muscle cancer	0.000475	0.153	CbGdCrCtD
Ruxolitinib—CLK2—tendon—muscle cancer	0.000474	0.00521	CbGeAlD
Ruxolitinib—DAPK2—vagina—muscle cancer	0.000472	0.00519	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—muscle cancer	0.000469	0.00516	CbGeAlD
Ruxolitinib—STK16—vagina—muscle cancer	0.000465	0.00511	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—muscle cancer	0.000463	0.0051	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—muscle cancer	0.000463	0.0051	CbGeAlD
Ruxolitinib—JAK3—head—muscle cancer	0.00046	0.00506	CbGeAlD
Ruxolitinib—CLK2—bone marrow—muscle cancer	0.000459	0.00505	CbGeAlD
Ruxolitinib—DCLK1—head—muscle cancer	0.000457	0.00503	CbGeAlD
Ruxolitinib—JAK1—head—muscle cancer	0.000457	0.00503	CbGeAlD
Ruxolitinib—TYK2—renal system—muscle cancer	0.000452	0.00497	CbGeAlD
Ruxolitinib—CAMK1D—head—muscle cancer	0.000446	0.00491	CbGeAlD
Ruxolitinib—BMPR2—tendon—muscle cancer	0.000446	0.00491	CbGeAlD
Ruxolitinib—MKNK2—renal system—muscle cancer	0.000446	0.00491	CbGeAlD
Ruxolitinib—JAK3—testis—muscle cancer	0.000445	0.00489	CbGeAlD
Ruxolitinib—DAPK3—vagina—muscle cancer	0.000444	0.00488	CbGeAlD
Ruxolitinib—PHKG2—head—muscle cancer	0.000444	0.00488	CbGeAlD
Ruxolitinib—JAK1—testis—muscle cancer	0.000442	0.00486	CbGeAlD
Ruxolitinib—DCLK1—testis—muscle cancer	0.000442	0.00486	CbGeAlD
Ruxolitinib—CLK2—vagina—muscle cancer	0.00044	0.00484	CbGeAlD
Ruxolitinib—PLK4—testis—muscle cancer	0.000439	0.00483	CbGeAlD
Ruxolitinib—RET—renal system—muscle cancer	0.000435	0.00478	CbGeAlD
Ruxolitinib—CAMK1D—testis—muscle cancer	0.000431	0.00474	CbGeAlD
Ruxolitinib—STK16—head—muscle cancer	0.000429	0.00472	CbGeAlD
Ruxolitinib—PHKG2—testis—muscle cancer	0.000429	0.00471	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—muscle cancer	0.000427	0.0047	CbGeAlD
Ruxolitinib—HIPK2—head—muscle cancer	0.000427	0.0047	CbGeAlD
Ruxolitinib—DAPK2—testis—muscle cancer	0.000421	0.00463	CbGeAlD
Ruxolitinib—MAP3K19—head—muscle cancer	0.000418	0.0046	CbGeAlD
Ruxolitinib—STK16—testis—muscle cancer	0.000415	0.00456	CbGeAlD
Ruxolitinib—BMPR2—vagina—muscle cancer	0.000414	0.00455	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—muscle cancer	0.000413	0.00454	CbGeAlD
Ruxolitinib—HIPK2—testis—muscle cancer	0.000412	0.00454	CbGeAlD
Ruxolitinib—MAP3K7—cardiac atrium—muscle cancer	0.000412	0.00453	CbGeAlD
Ruxolitinib—JAK2—renal system—muscle cancer	0.000411	0.00452	CbGeAlD
Ruxolitinib—DAPK3—head—muscle cancer	0.00041	0.00451	CbGeAlD
Ruxolitinib—CLK2—head—muscle cancer	0.000406	0.00447	CbGeAlD
Ruxolitinib—TYK2—cardiac atrium—muscle cancer	0.000405	0.00445	CbGeAlD
Ruxolitinib—MAP3K19—testis—muscle cancer	0.000404	0.00444	CbGeAlD
Ruxolitinib—MKNK2—cardiac atrium—muscle cancer	0.000399	0.00439	CbGeAlD
Ruxolitinib—BMP2K—tendon—muscle cancer	0.000399	0.00439	CbGeAlD
Ruxolitinib—CAMK2G—tendon—muscle cancer	0.000399	0.00439	CbGeAlD
Ruxolitinib—DAPK3—testis—muscle cancer	0.000396	0.00436	CbGeAlD
Ruxolitinib—LRRK2—tendon—muscle cancer	0.000396	0.00435	CbGeAlD
Ruxolitinib—NUAK2—vagina—muscle cancer	0.000396	0.00435	CbGeAlD
Ruxolitinib—ROCK1—head—muscle cancer	0.000394	0.00433	CbGeAlD
Ruxolitinib—CLK2—testis—muscle cancer	0.000392	0.00432	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—muscle cancer	0.000387	0.00425	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—muscle cancer	0.000387	0.00425	CbGeAlD
Ruxolitinib—DYRK1A—head—muscle cancer	0.000384	0.00422	CbGeAlD
Ruxolitinib—LRRK2—bone marrow—muscle cancer	0.000383	0.00422	CbGeAlD
Ruxolitinib—BMPR2—head—muscle cancer	0.000383	0.00421	CbGeAlD
Ruxolitinib—ROCK1—testis—muscle cancer	0.00038	0.00418	CbGeAlD
Ruxolitinib—DYRK1A—testis—muscle cancer	0.000371	0.00408	CbGeAlD
Ruxolitinib—BMP2K—vagina—muscle cancer	0.000371	0.00408	CbGeAlD
Ruxolitinib—CAMK2G—vagina—muscle cancer	0.000371	0.00408	CbGeAlD
Ruxolitinib—BMPR2—testis—muscle cancer	0.00037	0.00406	CbGeAlD
Ruxolitinib—JAK2—cardiac atrium—muscle cancer	0.000368	0.00405	CbGeAlD
Ruxolitinib—LRRK2—vagina—muscle cancer	0.000367	0.00404	CbGeAlD
Ruxolitinib—TAOK3—renal system—muscle cancer	0.000361	0.00397	CbGeAlD
Ruxolitinib—MAP3K7—tendon—muscle cancer	0.000359	0.00395	CbGeAlD
Ruxolitinib—MAP3K3—cardiac atrium—muscle cancer	0.000355	0.0039	CbGeAlD
Ruxolitinib—NUAK2—testis—muscle cancer	0.000353	0.00388	CbGeAlD
Ruxolitinib—TYK2—tendon—muscle cancer	0.000353	0.00388	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—muscle cancer	0.000351	0.00386	CbGeAlD
Ruxolitinib—MKNK2—tendon—muscle cancer	0.000348	0.00383	CbGeAlD
Ruxolitinib—IRAK1—tendon—muscle cancer	0.000348	0.00383	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—muscle cancer	0.000348	0.00383	CbGeAlD
Ruxolitinib—Bone pain—Vincristine—muscle cancer	0.000347	0.0308	CcSEcCtD
Ruxolitinib—CAMK2G—head—muscle cancer	0.000342	0.00377	CbGeAlD
Ruxolitinib—BMP2K—head—muscle cancer	0.000342	0.00377	CbGeAlD
Ruxolitinib—TYK2—bone marrow—muscle cancer	0.000342	0.00376	CbGeAlD
Ruxolitinib—RET—tendon—muscle cancer	0.00034	0.00373	CbGeAlD
Ruxolitinib—LRRK2—head—muscle cancer	0.000339	0.00373	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—muscle cancer	0.000337	0.00371	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—muscle cancer	0.000337	0.00371	CbGeAlD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—muscle cancer	0.000336	0.108	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—muscle cancer	0.000336	0.108	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—muscle cancer	0.000336	0.108	CbGdCrCtD
Ruxolitinib—MAP3K7—vagina—muscle cancer	0.000333	0.00367	CbGeAlD
Ruxolitinib—BMP2K—testis—muscle cancer	0.000331	0.00364	CbGeAlD
Ruxolitinib—CAMK2G—testis—muscle cancer	0.000331	0.00364	CbGeAlD
Ruxolitinib—LRRK2—testis—muscle cancer	0.000328	0.0036	CbGeAlD
Ruxolitinib—TYK2—vagina—muscle cancer	0.000327	0.0036	CbGeAlD
Ruxolitinib—TAOK3—cardiac atrium—muscle cancer	0.000324	0.00356	CbGeAlD
Ruxolitinib—MKNK2—vagina—muscle cancer	0.000323	0.00355	CbGeAlD
Ruxolitinib—JAK2—tendon—muscle cancer	0.000321	0.00353	CbGeAlD
Ruxolitinib—JAK2—bone marrow—muscle cancer	0.000311	0.00342	CbGeAlD
Ruxolitinib—MAP3K2—head—muscle cancer	0.000311	0.00342	CbGeAlD
Ruxolitinib—MAP3K3—tendon—muscle cancer	0.000309	0.0034	CbGeAlD
Ruxolitinib—TYK2—head—muscle cancer	0.000302	0.00333	CbGeAlD
Ruxolitinib—MAP3K2—testis—muscle cancer	0.0003	0.0033	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—muscle cancer	0.0003	0.0033	CbGeAlD
Ruxolitinib—MKNK2—head—muscle cancer	0.000298	0.00328	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—muscle cancer	0.000298	0.0264	CcSEcCtD
Ruxolitinib—JAK2—vagina—muscle cancer	0.000298	0.00328	CbGeAlD
Ruxolitinib—MAP3K7—testis—muscle cancer	0.000297	0.00327	CbGeAlD
Ruxolitinib—TYK2—testis—muscle cancer	0.000292	0.00321	CbGeAlD
Ruxolitinib—RET—head—muscle cancer	0.000291	0.0032	CbGeAlD
Ruxolitinib—MKNK2—testis—muscle cancer	0.000288	0.00317	CbGeAlD
Ruxolitinib—IRAK1—testis—muscle cancer	0.000288	0.00317	CbGeAlD
Ruxolitinib—MAP3K3—vagina—muscle cancer	0.000287	0.00316	CbGeAlD
Ruxolitinib—TAOK3—tendon—muscle cancer	0.000282	0.0031	CbGeAlD
Ruxolitinib—RET—testis—muscle cancer	0.000281	0.00309	CbGeAlD
Ruxolitinib—JAK2—head—muscle cancer	0.000275	0.00303	CbGeAlD
Ruxolitinib—TAOK3—bone marrow—muscle cancer	0.000273	0.003	CbGeAlD
Ruxolitinib—JAK2—testis—muscle cancer	0.000266	0.00292	CbGeAlD
Ruxolitinib—MAP3K3—head—muscle cancer	0.000265	0.00292	CbGeAlD
Ruxolitinib—TAOK3—vagina—muscle cancer	0.000262	0.00288	CbGeAlD
Ruxolitinib—MAP3K3—testis—muscle cancer	0.000256	0.00282	CbGeAlD
Ruxolitinib—TAOK3—head—muscle cancer	0.000242	0.00266	CbGeAlD
Ruxolitinib—TAOK3—testis—muscle cancer	0.000234	0.00257	CbGeAlD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—muscle cancer	0.000229	0.0739	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—muscle cancer	0.000229	0.0739	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—muscle cancer	0.000229	0.0739	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—muscle cancer	0.000229	0.0739	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—muscle cancer	0.000229	0.0739	CbGdCrCtD
Ruxolitinib—Pancytopenia—Dactinomycin—muscle cancer	0.000222	0.0197	CcSEcCtD
Ruxolitinib—Neutropenia—Dactinomycin—muscle cancer	0.000219	0.0194	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—muscle cancer	0.000214	0.019	CcSEcCtD
Ruxolitinib—Pancytopenia—Vincristine—muscle cancer	0.000198	0.0176	CcSEcCtD
Ruxolitinib—Neutropenia—Vincristine—muscle cancer	0.000195	0.0173	CcSEcCtD
Ruxolitinib—Weight decreased—Vincristine—muscle cancer	0.000189	0.0167	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—muscle cancer	0.000186	0.0165	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000173	0.0153	CcSEcCtD
Ruxolitinib—Pancytopenia—Etoposide—muscle cancer	0.000161	0.0142	CcSEcCtD
Ruxolitinib—Neutropenia—Etoposide—muscle cancer	0.000158	0.014	CcSEcCtD
Ruxolitinib—Infestation—Etoposide—muscle cancer	0.000151	0.0134	CcSEcCtD
Ruxolitinib—Infestation NOS—Etoposide—muscle cancer	0.000151	0.0134	CcSEcCtD
Ruxolitinib—Anaemia—Dactinomycin—muscle cancer	0.000151	0.0133	CcSEcCtD
Ruxolitinib—Bone pain—Doxorubicin—muscle cancer	0.000146	0.0129	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Etoposide—muscle cancer	0.000143	0.0126	CcSEcCtD
Ruxolitinib—Anaemia—Vincristine—muscle cancer	0.000134	0.0119	CcSEcCtD
Ruxolitinib—Infection—Dactinomycin—muscle cancer	0.000132	0.0117	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dactinomycin—muscle cancer	0.00013	0.0115	CcSEcCtD
Ruxolitinib—Infection—Vincristine—muscle cancer	0.000118	0.0105	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vincristine—muscle cancer	0.000116	0.0103	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vincristine—muscle cancer	0.000116	0.0103	CcSEcCtD
Ruxolitinib—Fatigue—Dactinomycin—muscle cancer	0.000115	0.0102	CcSEcCtD
Ruxolitinib—CYP3A4—renal system—muscle cancer	0.00011	0.00121	CbGeAlD
Ruxolitinib—Anaemia—Etoposide—muscle cancer	0.000109	0.00965	CcSEcCtD
Ruxolitinib—Body temperature increased—Dactinomycin—muscle cancer	0.000105	0.00931	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000103	0.00908	CcSEcCtD
Ruxolitinib—Fatigue—Vincristine—muscle cancer	0.000102	0.00907	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000102	0.009	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	9.96e-05	0.00883	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—muscle cancer	9.62e-05	0.00853	CcSEcCtD
Ruxolitinib—Infection—Etoposide—muscle cancer	9.56e-05	0.00847	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—muscle cancer	9.54e-05	0.00845	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—muscle cancer	9.47e-05	0.0084	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Etoposide—muscle cancer	9.42e-05	0.00835	CcSEcCtD
Ruxolitinib—Body temperature increased—Vincristine—muscle cancer	9.39e-05	0.00832	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—muscle cancer	9.34e-05	0.00828	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—muscle cancer	9.03e-05	0.00801	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—muscle cancer	9.03e-05	0.00801	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	8.95e-05	0.00793	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—muscle cancer	8.61e-05	0.00763	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—muscle cancer	8.54e-05	0.00757	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—muscle cancer	8.52e-05	0.00755	CcSEcCtD
Ruxolitinib—Asthenia—Vincristine—muscle cancer	8.52e-05	0.00755	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—muscle cancer	8.33e-05	0.00738	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—muscle cancer	8.3e-05	0.00736	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—muscle cancer	8.29e-05	0.00735	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—muscle cancer	8.2e-05	0.00727	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—muscle cancer	8.15e-05	0.00722	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—muscle cancer	8.11e-05	0.00719	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—muscle cancer	7.98e-05	0.00708	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—muscle cancer	7.94e-05	0.00703	CcSEcCtD
Ruxolitinib—Dizziness—Vincristine—muscle cancer	7.85e-05	0.00696	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—muscle cancer	7.82e-05	0.00693	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—muscle cancer	7.82e-05	0.00693	CcSEcCtD
Ruxolitinib—Body temperature increased—Etoposide—muscle cancer	7.6e-05	0.00674	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—muscle cancer	7.6e-05	0.00674	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—muscle cancer	7.46e-05	0.00661	CcSEcCtD
Ruxolitinib—Headache—Vincristine—muscle cancer	7.44e-05	0.00659	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—muscle cancer	7.4e-05	0.00656	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—muscle cancer	7.38e-05	0.00654	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—muscle cancer	7.06e-05	0.00626	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—muscle cancer	7.06e-05	0.00625	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—muscle cancer	7.02e-05	0.00622	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—muscle cancer	6.9e-05	0.00612	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—muscle cancer	6.81e-05	0.00603	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—muscle cancer	6.52e-05	0.00578	CcSEcCtD
Ruxolitinib—Dizziness—Etoposide—muscle cancer	6.36e-05	0.00564	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—muscle cancer	6.11e-05	0.00542	CcSEcCtD
Ruxolitinib—Headache—Etoposide—muscle cancer	6.03e-05	0.00534	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—muscle cancer	6.02e-05	0.00534	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	5.97e-05	0.00529	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—muscle cancer	5.72e-05	0.00507	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—muscle cancer	5.65e-05	0.00501	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—muscle cancer	5.65e-05	0.00501	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—muscle cancer	5.64e-05	0.005	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—muscle cancer	5.6e-05	0.00496	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	5.17e-05	0.00458	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—muscle cancer	4.97e-05	0.00441	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—muscle cancer	4.97e-05	0.0044	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—muscle cancer	4.96e-05	0.00439	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—muscle cancer	4.89e-05	0.00434	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—muscle cancer	4.88e-05	0.00433	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—muscle cancer	4.85e-05	0.00429	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—muscle cancer	4.55e-05	0.00404	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	4.31e-05	0.00382	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—muscle cancer	4.3e-05	0.00381	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—muscle cancer	4.13e-05	0.00366	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—muscle cancer	4.08e-05	0.00361	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—muscle cancer	3.94e-05	0.0035	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—muscle cancer	3.81e-05	0.00338	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—muscle cancer	3.61e-05	0.0032	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—muscle cancer	3.58e-05	0.00317	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—muscle cancer	3.53e-05	0.00313	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—muscle cancer	3.3e-05	0.00292	CcSEcCtD
Ruxolitinib—JAK2—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	3.24e-05	0.000323	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—FOXO1—muscle cancer	3.24e-05	0.000323	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—CDKN2A—muscle cancer	3.24e-05	0.000323	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB4—MDM2—muscle cancer	3.22e-05	0.000321	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—FOXO4—muscle cancer	3.21e-05	0.00032	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	3.21e-05	0.00032	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—FOXO4—muscle cancer	3.2e-05	0.000319	CbGpPWpGaD
Ruxolitinib—ROCK1—Apoptosis—TP53—muscle cancer	3.2e-05	0.000319	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—KIT—muscle cancer	3.17e-05	0.000316	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IGF2—muscle cancer	3.17e-05	0.000316	CbGpPWpGaD
Ruxolitinib—PRKG2—Hemostasis—TP53—muscle cancer	3.15e-05	0.000314	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—MDM2—muscle cancer	3.14e-05	0.000313	CbGpPWpGaD
Ruxolitinib—Headache—Doxorubicin—muscle cancer	3.13e-05	0.00277	CcSEcCtD
Ruxolitinib—PRKG2—Signaling Pathways—FOXO1—muscle cancer	3.1e-05	0.000309	CbGpPWpGaD
Ruxolitinib—MAP3K7—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	3.09e-05	0.000308	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—CNR1—muscle cancer	3.08e-05	0.000307	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—MDM2—muscle cancer	3.08e-05	0.000307	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—FOXO4—muscle cancer	3.07e-05	0.000306	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—MDM2—muscle cancer	3.06e-05	0.000305	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by VEGF—VEGFA—muscle cancer	3.06e-05	0.000305	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB2—MDM2—muscle cancer	3.05e-05	0.000304	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—MDM2—muscle cancer	3.03e-05	0.000302	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—CNR1—muscle cancer	3.03e-05	0.000302	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—FOXO4—muscle cancer	3.03e-05	0.000302	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—CDKN2A—muscle cancer	3.02e-05	0.000301	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—ENO2—muscle cancer	2.95e-05	0.000294	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—MDM2—muscle cancer	2.93e-05	0.000292	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—FOXO1—muscle cancer	2.92e-05	0.000291	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD34—muscle cancer	2.91e-05	0.00029	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—KIT—muscle cancer	2.87e-05	0.000286	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IGF2—muscle cancer	2.87e-05	0.000286	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—MDM2—muscle cancer	2.85e-05	0.000284	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	2.85e-05	0.000284	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—MDM2—muscle cancer	2.85e-05	0.000284	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD34—muscle cancer	2.83e-05	0.000282	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—MDM2—muscle cancer	2.83e-05	0.000282	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—MDM2—muscle cancer	2.8e-05	0.000279	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CNR1—muscle cancer	2.8e-05	0.000279	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—MDM2—muscle cancer	2.79e-05	0.000278	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIDINS220—muscle cancer	2.78e-05	0.000277	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—FOXO1—muscle cancer	2.76e-05	0.000275	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CNR1—muscle cancer	2.75e-05	0.000274	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD34—muscle cancer	2.74e-05	0.000273	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—MDM2—muscle cancer	2.73e-05	0.000272	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PTCH1—muscle cancer	2.7e-05	0.000269	CbGpPWpGaD
Ruxolitinib—CAMK2G—Cellular responses to stress—TP53—muscle cancer	2.68e-05	0.000267	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HMGA1—muscle cancer	2.68e-05	0.000267	CbGpPWpGaD
Ruxolitinib—MAP3K7—TGF-beta Signaling Pathway—TP53—muscle cancer	2.65e-05	0.000264	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—FOXO1—muscle cancer	2.65e-05	0.000264	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—MDM2—muscle cancer	2.64e-05	0.000263	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—FOXO1—muscle cancer	2.64e-05	0.000263	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—FOXO4—muscle cancer	2.6e-05	0.00026	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—MDM2—muscle cancer	2.57e-05	0.000256	CbGpPWpGaD
Ruxolitinib—DYRK1A—Cell Cycle—TP53—muscle cancer	2.53e-05	0.000252	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	2.53e-05	0.000252	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—KIT—muscle cancer	2.52e-05	0.000251	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—FOXO1—muscle cancer	2.51e-05	0.00025	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—FOXO4—muscle cancer	2.5e-05	0.000249	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—MDM2—muscle cancer	2.5e-05	0.000249	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—KIT—muscle cancer	2.47e-05	0.000246	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PTCH1—muscle cancer	2.45e-05	0.000244	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—FOXO1—muscle cancer	2.45e-05	0.000244	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—FOXO1—muscle cancer	2.44e-05	0.000243	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—FOXO1—muscle cancer	2.43e-05	0.000242	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—PTGS2—muscle cancer	2.41e-05	0.00024	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—FOXO4—muscle cancer	2.4e-05	0.00024	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—VEGFA—muscle cancer	2.39e-05	0.000238	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—FOXO1—muscle cancer	2.37e-05	0.000236	CbGpPWpGaD
Ruxolitinib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	2.37e-05	0.000236	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—FOXO1—muscle cancer	2.36e-05	0.000236	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—KIT—muscle cancer	2.36e-05	0.000236	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—VEGFA—muscle cancer	2.35e-05	0.000234	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—FOXO4—muscle cancer	2.32e-05	0.000231	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—VEGFA—muscle cancer	2.3e-05	0.000229	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CNR1—muscle cancer	2.28e-05	0.000227	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTCH1—muscle cancer	2.28e-05	0.000227	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—FOXO1—muscle cancer	2.27e-05	0.000226	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—MDM2—muscle cancer	2.26e-05	0.000225	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—FOXO1—muscle cancer	2.24e-05	0.000223	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IGF2—muscle cancer	2.23e-05	0.000222	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—KIT—muscle cancer	2.22e-05	0.000222	CbGpPWpGaD
Ruxolitinib—MAP3K7—MAPK Signaling Pathway—TP53—muscle cancer	2.19e-05	0.000218	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—PTGS2—muscle cancer	2.18e-05	0.000217	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ENO2—muscle cancer	2.18e-05	0.000217	CbGpPWpGaD
Ruxolitinib—PRKG2—Metabolism—PTGS2—muscle cancer	2.15e-05	0.000214	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD34—muscle cancer	2.14e-05	0.000214	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—FOXO1—muscle cancer	2.09e-05	0.000208	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CNR1—muscle cancer	2.07e-05	0.000206	CbGpPWpGaD
Ruxolitinib—JAK2—Factors involved in megakaryocyte development and platelet production—TP53—muscle cancer	2.02e-05	0.000201	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KIT—muscle cancer	2.02e-05	0.000201	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KIT—muscle cancer	2.01e-05	0.0002	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—MDM2—muscle cancer	1.98e-05	0.000197	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—FOXO4—muscle cancer	1.98e-05	0.000197	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HMGA1—muscle cancer	1.98e-05	0.000197	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTCH1—muscle cancer	1.96e-05	0.000195	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—FOXO4—muscle cancer	1.96e-05	0.000195	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—MDM2—muscle cancer	1.94e-05	0.000194	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—VEGFA—muscle cancer	1.94e-05	0.000194	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTCH1—muscle cancer	1.93e-05	0.000192	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—FOXO1—muscle cancer	1.92e-05	0.000192	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—FOXO4—muscle cancer	1.92e-05	0.000192	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CNR1—muscle cancer	1.92e-05	0.000191	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KIT—muscle cancer	1.91e-05	0.000191	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—FOXO4—muscle cancer	1.86e-05	0.000186	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KIT—muscle cancer	1.86e-05	0.000186	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—MDM2—muscle cancer	1.86e-05	0.000186	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IGF2—muscle cancer	1.86e-05	0.000185	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KIT—muscle cancer	1.86e-05	0.000185	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PTCH1—muscle cancer	1.85e-05	0.000185	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KIT—muscle cancer	1.85e-05	0.000184	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—FOXO1—muscle cancer	1.85e-05	0.000184	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—PTGS2—muscle cancer	1.83e-05	0.000182	CbGpPWpGaD
Ruxolitinib—JAK2—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.81e-05	0.000181	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KIT—muscle cancer	1.81e-05	0.00018	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—TP53—muscle cancer	1.8e-05	0.00018	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KIT—muscle cancer	1.8e-05	0.00018	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—FOXO1—muscle cancer	1.78e-05	0.000177	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—FOXO4—muscle cancer	1.78e-05	0.000177	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—VEGFA—muscle cancer	1.76e-05	0.000176	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—MDM2—muscle cancer	1.75e-05	0.000174	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TP53—muscle cancer	1.74e-05	0.000173	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KIT—muscle cancer	1.73e-05	0.000172	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CNR1—muscle cancer	1.72e-05	0.000172	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—FOXO1—muscle cancer	1.71e-05	0.000171	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—VEGFA—muscle cancer	1.7e-05	0.00017	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KIT—muscle cancer	1.7e-05	0.00017	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—FOXO4—muscle cancer	1.68e-05	0.000168	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—TP53—muscle cancer	1.68e-05	0.000167	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—VEGFA—muscle cancer	1.68e-05	0.000167	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—VEGFA—muscle cancer	1.67e-05	0.000167	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—FOXO4—muscle cancer	1.66e-05	0.000165	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CNR1—muscle cancer	1.65e-05	0.000165	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ENO2—muscle cancer	1.65e-05	0.000164	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CNR1—muscle cancer	1.63e-05	0.000162	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—MDM2—muscle cancer	1.59e-05	0.000158	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MDM2—muscle cancer	1.58e-05	0.000158	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF2—muscle cancer	1.57e-05	0.000157	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CNR1—muscle cancer	1.57e-05	0.000156	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—MDM2—muscle cancer	1.51e-05	0.00015	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HMGA1—muscle cancer	1.5e-05	0.000149	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTCH1—muscle cancer	1.49e-05	0.000148	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—muscle cancer	1.47e-05	0.000146	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MDM2—muscle cancer	1.47e-05	0.000146	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KIT—muscle cancer	1.47e-05	0.000146	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—MDM2—muscle cancer	1.46e-05	0.000146	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—FOXO1—muscle cancer	1.46e-05	0.000146	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FOXO4—muscle cancer	1.46e-05	0.000145	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MDM2—muscle cancer	1.46e-05	0.000145	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—FOXO1—muscle cancer	1.45e-05	0.000144	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTCH1—muscle cancer	1.45e-05	0.000144	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—MDM2—muscle cancer	1.42e-05	0.000142	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—FOXO1—muscle cancer	1.42e-05	0.000141	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MDM2—muscle cancer	1.42e-05	0.000141	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTGS2—muscle cancer	1.42e-05	0.000141	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—VEGFA—muscle cancer	1.41e-05	0.000141	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KIT—muscle cancer	1.41e-05	0.00014	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTCH1—muscle cancer	1.4e-05	0.00014	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—FOXO1—muscle cancer	1.38e-05	0.000137	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—MDM2—muscle cancer	1.36e-05	0.000136	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KIT—muscle cancer	1.35e-05	0.000135	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF2—muscle cancer	1.35e-05	0.000135	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FOXO4—muscle cancer	1.35e-05	0.000134	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—MDM2—muscle cancer	1.34e-05	0.000134	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—VEGFA—muscle cancer	1.34e-05	0.000133	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—VEGFA—muscle cancer	1.33e-05	0.000132	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF2—muscle cancer	1.33e-05	0.000132	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—FOXO1—muscle cancer	1.31e-05	0.000131	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KIT—muscle cancer	1.31e-05	0.00013	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FOXO4—muscle cancer	1.28e-05	0.000128	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—muscle cancer	1.26e-05	0.000126	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—VEGFA—muscle cancer	1.26e-05	0.000125	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CNR1—muscle cancer	1.26e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—FOXO1—muscle cancer	1.24e-05	0.000124	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FOXO4—muscle cancer	1.24e-05	0.000124	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—FOXO1—muscle cancer	1.22e-05	0.000122	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CNR1—muscle cancer	1.22e-05	0.000122	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FOXO4—muscle cancer	1.21e-05	0.00012	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—VEGFA—muscle cancer	1.2e-05	0.00012	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CNR1—muscle cancer	1.18e-05	0.000118	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MDM2—muscle cancer	1.15e-05	0.000115	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KIT—muscle cancer	1.11e-05	0.000111	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MDM2—muscle cancer	1.11e-05	0.00011	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KIT—muscle cancer	1.1e-05	0.00011	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTCH1—muscle cancer	1.1e-05	0.000109	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KIT—muscle cancer	1.08e-05	0.000108	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FOXO1—muscle cancer	1.08e-05	0.000107	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—muscle cancer	1.07e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MDM2—muscle cancer	1.07e-05	0.000106	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KIT—muscle cancer	1.05e-05	0.000105	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MDM2—muscle cancer	1.03e-05	0.000102	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF2—muscle cancer	1.03e-05	0.000102	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—muscle cancer	1.03e-05	0.000102	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—muscle cancer	1e-05	0.0001	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KIT—muscle cancer	9.99e-06	9.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF2—muscle cancer	9.98e-06	9.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FOXO1—muscle cancer	9.94e-06	9.9e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF2—muscle cancer	9.68e-06	9.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—VEGFA—muscle cancer	9.53e-06	9.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KIT—muscle cancer	9.48e-06	9.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FOXO1—muscle cancer	9.46e-06	9.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FOXO4—muscle cancer	9.42e-06	9.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—VEGFA—muscle cancer	9.35e-06	9.32e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KIT—muscle cancer	9.32e-06	9.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CNR1—muscle cancer	9.25e-06	9.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FOXO1—muscle cancer	9.18e-06	9.15e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—muscle cancer	9.08e-06	9.05e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FOXO1—muscle cancer	8.91e-06	8.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MDM2—muscle cancer	8.78e-06	8.75e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MDM2—muscle cancer	8.68e-06	8.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MDM2—muscle cancer	8.52e-06	8.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MDM2—muscle cancer	8.27e-06	8.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KIT—muscle cancer	8.2e-06	8.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MDM2—muscle cancer	7.87e-06	7.84e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—muscle cancer	7.81e-06	7.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—muscle cancer	7.58e-06	7.56e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FH—muscle cancer	7.58e-06	7.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KIT—muscle cancer	7.57e-06	7.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF2—muscle cancer	7.56e-06	7.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MDM2—muscle cancer	7.46e-06	7.44e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MDM2—muscle cancer	7.34e-06	7.31e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KIT—muscle cancer	7.21e-06	7.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—muscle cancer	7.07e-06	7.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KIT—muscle cancer	7e-06	6.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FOXO1—muscle cancer	6.96e-06	6.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KIT—muscle cancer	6.79e-06	6.76e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—muscle cancer	6.59e-06	6.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MDM2—muscle cancer	6.46e-06	6.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MDM2—muscle cancer	5.96e-06	5.94e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—muscle cancer	5.9e-06	5.88e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—muscle cancer	5.75e-06	5.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MDM2—muscle cancer	5.68e-06	5.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—muscle cancer	5.67e-06	5.65e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—muscle cancer	5.57e-06	5.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MDM2—muscle cancer	5.51e-06	5.49e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MDM2—muscle cancer	5.34e-06	5.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—muscle cancer	5.3e-06	5.28e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—muscle cancer	4.98e-06	4.96e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—muscle cancer	4.31e-06	4.29e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MED12—muscle cancer	4.28e-06	4.27e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—muscle cancer	4.28e-06	4.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—muscle cancer	4.21e-06	4.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—muscle cancer	4.18e-06	4.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—muscle cancer	4.18e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—muscle cancer	4.06e-06	4.04e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—muscle cancer	3.91e-06	3.89e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—muscle cancer	3.26e-06	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—muscle cancer	3.17e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—muscle cancer	3.16e-06	3.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—muscle cancer	3.07e-06	3.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—muscle cancer	2.4e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—muscle cancer	1.36e-06	1.36e-05	CbGpPWpGaD
